Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21953819 | 0.80 | CYSLTR2 (0.42) | PTK2SYKNPC1RAB9AHSD17B10 | |
| SCHEMBL21953511 | 0.77 | SYK (0.38) | PTK2PRKCZSYKIDO1SMN1; SMN2 | |
| SCHEMBL16448309 | 0.74 | RARA (0.49) | PDGFRBPDGFRANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16446429 | 0.74 | RARA (0.49) | PDGFRBPDGFRANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16446789 | 0.72 | RARA (0.47) | PDGFRBPDGFRANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21953552 | 0.72 | EP300 (0.37) | SYK | |
| SCHEMBL21879656 | 0.71 | PTK2 (0.39) | PTK2SYKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2856840 | 0.70 | CA12 (0.47) | PDGFRBPDGFRANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23409701 | 0.70 | CA12 (0.58) | PRKCZNPC1RAB9ASMN1; SMN2RARA | |
| SCHEMBL18832302 | 0.69 | RAB9A (0.51) | PDGFRBPDGFRANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016006921-A1 | ACUTE MYELOID LEUKEMIA TARGETED THERAPEUTIC AGENT WITH REDUCED DRUG SIDE EFFECTS | 한국과학기술연구원 | 2016-01-14 | — | — | WO | disclosed |
| US-8586580-B2 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8586580-B2 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| EP-2491043-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KIST Korea Institute of Science and Technology (KR) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, TK1, DTYMK | PTK2 292/4885PRKCZ 132/4885SYK 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.